Loading
Century Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cowan Chad, was filed 29 Dec 2025.
Century Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Century Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (21 October 2025 to 21 October 2026), 44 filings came from 6 insiders.
Both sides are active: 3 purchases worth €83k and 19 sales worth €74k, from 2 insiders and 4 insiders respectively. The net balance comes to €8,907 on the buying side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 senior executive and 1 chief executive. At €42k, the purchase published on 29 December 2025 by Cowan Chad is the largest of the period.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The last insider purchase was made public on 29 December 2025, 296 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,454 companies, median 22 filings), a count of 44 filings is above the norm. The full history, which starts in 2021, counts 4 purchases against 52 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 109.2 m USD and net income of -9.6 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
111
Thresholds
n/a
Buy Volume
€89,797
4 ops. · all time
Sell Volume
€7M
52 ops. · all time
Who traded when
BuySaleDouglas Carr16 sales
Gregory Russotti10 sales
Brent Pfeiffenberger2 buys6 sales
Farid Adrienne5 sales
Chad Cowan1 buy1 sale
Since the insiders bought
- +103.2%Entry US$1.00 · Close at T+90 US$2.03
- +243.3%Entry US$0.67 · Close at T+90 US$2.29
- -70.4%Entry US$1.66 · Close at T+365 US$0.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Century Therapeutics, Inc. Buy (bullish), based on 4 analysts. Average price target: US$4.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,675 of 26,281 companies
10.7
score / 100
Value14
Quality8
FCF yld-39%
Earn yld-3.6%
EV/EBITDA·
ROE-50%
Gross mgn·
Net mgn-8.8%
Debt/EBITDA16.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.47
Analyst consensus
4 analystsBuy
US$2.00Target US$4.75(+223%)US$8.00
Income statement
RevenueUS$109.2M
EBITDAUS$2.6M2% margin
Net income-US$9.6M-8.8% margin
Valuation
PER (forward)-3.3x
P/Book1.1x
Beta1.67
Balance sheet & cash
Market capUS$266.2M
Total debtUS$43.6M
Free Cash Flow-US$104.7M
Debt / Equity17%
Profitability & ownership
ROE-49.7%
ROA-23.5%
% insiders8.1%
% institutions87.5%
Last declaration on 15 September 2026
Declarations111 total
2,587 shares@ US$1.930.0015% mcap3.8% of flowCommon StockSEC:0001867305-26-000014:0
13,850 shares@ US$1.940.0083% mcap3.4% of flowCommon StockSEC:0002001162-26-000018:0
1,658 shares@ US$1.930.0010% mcap3.8% of flowCommon StockSEC:0001867173-26-000020:0
1,658 shares@ US$1.93050.0010% mcap3.8% of flowCommonSEC144:0001959173-26-006939
2,587 shares@ US$1.93050.0015% mcap3.8% of flowCommonSEC144:0001959173-26-006940
254 shares@ US$2.050.0002% mcap0.6% of flowCommon StockSEC:0001867173-26-000018:0
534 shares@ US$2.050.0003% mcap0.8% of flowCommon StockSEC:0001867305-26-000012:0
463 shares@ US$2.110.0003% mcap0.1% of flowCommon StockSEC:0002001162-26-000016:0
534 shares@ US$2.04950.0003% mcap0.8% of flowCommonSEC144:0001959173-26-006793
31,172 shares@ US$1.920.019% mcap7.6% of flowCommon StockSEC:0002001162-26-000014:0
275 shares@ US$1.9770.0002% mcap0.6% of flowCommon StockSEC:0001867173-26-000016:0
2,584 shares@ US$2.2324.2% of flowCommon StockSEC:0001867305-26-000010:0
1,654 shares@ US$2.2324.1% of flowCommon StockSEC:0001867173-26-000014:0
13,849 sharesCommon StockSEC:0002001162-26-000012:0
358 sharesCommon StockSEC:0002039294-26-000010:0
2,584 shares@ US$2.23210.0014% mcap4.4% of flowCommonSEC144:0001959173-26-004611
249 shares@ US$2.1110.6% of flowCommon StockSEC:0001867173-26-000012:0
524 shares@ US$2.1110.8% of flowCommon StockSEC:0001867305-26-000008:0
463 shares@ US$2.130.0002% mcap0.1% of flowCommon StockSEC:0002001162-26-000010:0
524 shares@ US$2.11070.0003% mcap0.8% of flowCommonSEC144:0001959173-26-004436
1,365 shares@ US$2.195.0% of flowCommon StockSEC:0002039294-26-000008:0
10,076 shares@ US$2.54919.6% of flowCommon StockSEC:0001867305-26-000006:0
7,043 shares@ US$2.54921.2% of flowCommon StockSEC:0001867173-26-000008:0
1,431 shares@ US$2.736.5% of flowCommon StockSEC:0002039294-26-000006:0
55,397 shares@ US$2.7319.1% of flowCommon StockSEC:0002001162-26-000006:0
25 of 111 declarations
About Century Therapeutics, Inc.
Century Therapeutics, Inc. (ticker: IPSC) is a U.S.-listed biotechnology company trading on NASDAQ in the United States. For French-, Belgian- and Swiss-based investors, this is a classic development-stage cell therapy story: a science-driven biotech with significant platform optionality, but whose investment case still depends on clinical execution, regulatory progress, financing discipline and eventual proof that its engineered products can translate into durable therapeutic benefit.
Century was founded in 2018 by Versant Ventures and launched in 2019 with an initial $250 million financing. The company is headquartered in Philadelphia, Pennsylvania, and maintains operating footprints in New Jersey and Boston, with an additional innovation presence in Seattle. Its strategic identity is built around an allogeneic induced pluripotent stem cell (iPSC) platform combined with immune-evasion engineering. In practical terms, Century aims to create “off-the-shelf” cell therapies that could be manufactured at scale, potentially improving access, consistency and affordability versus more complex autologous cell therapy approaches.
Read moreShow less
The core business is the development of iPSC-derived therapies for cancer and autoimmune disease. Century’s platform integrates gene editing, protein engineering and manufacturing capabilities to generate differentiated product candidates under its Allo-Evasion™ approach. The most important pipeline programs currently highlighted by management are CNTY-813, an islet replacement therapy for type 1 diabetes with functional-cure potential, and CNTY-308, a CD19-targeted CAR-iT program being advanced for B-cell mediated autoimmune diseases and with relevance to oncology applications. In 2025, the company re-prioritized its preclinical pipeline to focus resources on a smaller number of programs considered the most transformational.
From a competitive standpoint, Century operates in a crowded and highly capital-intensive field that includes cell-therapy developers, iPSC platform companies and other allogeneic immunotherapy players. Its potential differentiation lies in combining a scalable iPSC manufacturing model with engineered immune evasion and a focus on high-unmet-need indications. That said, the company remains exposed to the usual biotech risks: clinical failure, regulatory delays, manufacturing complexity and the need to continually secure capital.
Recent developments are material. In January 2026, Century completed an oversubscribed $135 million private placement, extending cash runway into 1Q 2029. In May 2026, the company reported that CNTY-813 remained on track for an IND submission in 4Q 2026, with initial clinical data expected in 2H 2027, while CNTY-308 was also advancing toward clinic in 2026. These updates, together with the company’s ongoing SEC Form 4 insider transaction filings, make IPSC a name that investors typically monitor for catalyst-driven volatility rather than current operating profitability.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
